Drugs / Mesenchymal Stem Cell-Derived Exosome
Mesenchymal Stem Cell-Derived Exosome
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07103980 | Jul 2024 → Jul 2025 overdue | post-infectious syndrome | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07466953 | Apr → Dec 2026 expected | — | Mert Ersan | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesenchymal stem cell derived exosome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07103980 ↗ |
| Modality | Other / unclassified | “mesenchymal stem cell-derived suspended exosome preparation” NCT07466953 ↗ |
| Route | Inhaled | “Mesenchymal stem cell derived exosome nebulization (FITCELL 5ml nebulization QD)” NCT07103980 ↗ |